CELG-RI

Healthcare

Bristol-Myers Squibb Company Ce · Drug Manufacturers - General · $220M

UQS Score — Balanced Preset
68.6
Good

Bristol-Myers Squibb Company Ce scores 68.6/100 using the Balanced preset.

UQS vs Healthcare Sector
CELG-RI
68.6
Sector avg
32.4
Quality
Strong
Moat
Neutral
Growth
Good
Risk
Weak
Valuation
Attractive

Unlock Full CELG-RI Analysis

Sign in to unlock the detailed analysis behind the UQS Score.

  • Detailed 6-pillar UQS breakdown with exact scores
  • All 29 metrics with sector-calibrated comparisons
  • 6 investor presets (Buffett, Munger, Lynch, Wood, Graham, Balanced)
  • Watchlist tracking with score alerts
  • AI-generated investment perspectives across 6 preset views
  • Score history chart with change notifications
Analyze CELG-RI in Detail →

Pro Analysis

CELG-RI — Score History

5560657075Apr 11Apr 29May 17Jun 4Jun 22Jul 9v5
Score changes· 7 most recent
DateUQSQualityMoatGrowthRiskValueChange
Jul 8, 202668.692.448.071.927.8100.00.0
Jul 1, 202668.692.448.071.827.8100.00.0
Jun 8, 202668.692.448.071.627.8100.00.0
Jun 3, 202668.692.448.071.727.8100.0+6.4
May 11, 202662.290.348.042.227.8100.0-0.4
Apr 12, 202662.692.048.042.227.8100.0-0.5
Apr 11, 202663.192.050.042.227.8100.0

CELG-RI — Pillar Breakdown

Quality

92.4/100 (25%)

Bristol-Myers Squibb Company Ce demonstrates outstanding capital efficiency and profitability, placing it among the highest-quality businesses in the market.

Capital Efficiency (ROIC)Moderate

How effectively capital is deployed to generate returns.

Return on EquityStrong

Profitability relative to shareholders' equity.

Operating ProfitabilityStrong

Ability to convert revenue into operating profit.

Net ProfitabilityStrong

Bottom-line profit as a share of revenue.

Gross Profit / AssetsStrong

Asset productivity — how much gross profit each dollar of assets generates.

Cash GenerationStrong

Free cash flow relative to market value.

Growth

71.9/100 (20%)

Bristol-Myers Squibb Company Ce demonstrates healthy growth trends across revenue and earnings.

Recent Revenue TrendModerate

Revenue trajectory over the last twelve months.

3Y Revenue CAGRModerate

Compound annual revenue growth rate over 3 years.

EPS GrowthStrong

Year-over-year earnings per share growth.

Forward Revenue OutlookStrong

Analyst consensus for future revenue growth.

Forward EPS GrowthWeak

Analyst consensus for future earnings growth.

Risk

27.8/100 (15%)

Bristol-Myers Squibb Company Ce presents elevated risk with concerns around leverage or financial stability.

Financial LeverageWeak

Debt levels relative to earnings capacity.

Debt/EquityWeak

Total debt relative to shareholder equity.

Current RatioModerate

Short-term liquidity — ability to pay near-term obligations.

Interest CoverageModerate

Earnings capacity relative to interest payments.

Valuation

100.0/100 (15%)

Bristol-Myers Squibb Company Ce appears attractively valued relative to its earnings, cash flows, and sector peers.

Earnings YieldStrong

Inverse of forward P/E — higher yield means cheaper stock.

Price to Free Cash FlowStrong

How many years of FCF the market cap represents.

PEG RatioStrong

P/E relative to earnings growth — lower is more attractive.

Moat

48/100 (25%)

Bristol-Myers Squibb Company Ce possesses some competitive advantages but faces meaningful competition. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CELG-RI.

Score Composition

Quality
92.4×25%23.1
Growth
71.9×20%14.4
Risk
27.8×15%4.2
Valuation
100.0×15%15.0
Moat
48.0×25%12.0
Total
68.6Good

Financial Data

More Stock Analysis

How is the CELG-RI UQS Score Calculated?

The UQS (Unified Quality Score) for Bristol-Myers Squibb Company Ce is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.

Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.

Moat (25%) assesses Bristol-Myers Squibb Company Ce's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.

Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.

Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.

Valuation (15%) measures whether Bristol-Myers Squibb Company Ce is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.

Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.